Results 181 to 190 of about 1,190,584 (342)

Engineering tandem VHHs to target different epitopes to enhance antibody‐dependent cell‐mediated cytotoxicity

FEBS Open Bio, EarlyView.
Tandem VHH targeting distinct EGFR epitopes were engineered into a monovalent bispecific antibody (7D12‐EGA1‐Fc) with more potent ADCC without increasing affinity to EGFR. Structural modeling of 7D12‐EGA1‐Fc showed cross‐linking of separate EGFR domains to enhance CD16a engagement on NK cells.
Yuqiang Xu, Hao Jiang, Limin Chen, Fulai Zhou, Ying Jin, Mark L. Chiu   +5 more
wiley   +1 more source

Ivonescimab: promise or reality for advanced non-small cell lung cancer? [PDF]

Transl Lung Cancer Res
Olivares-Hernández A, Santa-Catalina PG, Fonseca-Sánchez E, Del Barco-Morillo E.   +3 more
europepmc   +1 more source

FGFR Like1 drives esophageal cancer progression via EMT, PI3K/Akt, and notch signalling: insights from clinical data and next‐generation sequencing analysis

FEBS Open Bio, EarlyView.
Clinical analysis reveals significant dysregulation of FGFRL1 in esophageal cancer (EC) patients. RNAi‐coupled next‐generation sequencing (NGS) and in vitro study reveal FGFRL1‐mediated EC progression via EMT, PI3K/Akt, and Notch pathways. Functional assays confirm its role in tumor growth, migration, and invasion.
Aprajita Srivastava, Anoop Saraya, Deepak Gunjan, Rinu Sharma   +3 more
wiley   +1 more source

Unlocking the potential of immunotherapy for patients with resectable non-small cell lung cancer. [PDF]

Front Oncol
Patel SP, Gainor J, Kao S, Lee SH, Mok T, Shah R, Zhou C, Peters S.   +7 more
europepmc   +1 more source

KLK7 overexpression promotes an aggressive phenotype and facilitates peritoneal dissemination in colorectal cancer cells

FEBS Open Bio, EarlyView.
KLK7, a tissue kallikrein‐related peptidase, is elevated in advanced colorectal cancer and associated with shorter survival. High KLK7 levels in ascites correlate with peritoneal metastasis. In mice, KLK7 overexpression increases metastasis. In vitro, KLK7 enhances cancer cell proliferation, migration, adhesion, and spheroid formation, driving ...
Yosr Z. Haffani, Tobias Dreyer, Meriem Naim, Rea Lo Dico, Natalia A. Ignatenko, Viktor Magdolen, Dalila Darmoul   +6 more
wiley   +1 more source

Restoring expression of tumour suppressor PTEN by engineered circular RNA‐enhanced Osimertinib sensitivity in non‐small cell lung cancer

Clinical and Translational Medicine
Haoran Li, Zheng Liu, Shaoyi Chen, Jingsheng Cai, Peiyu Wang, Kezhong Chen, Mantang Qiu   +6 more
doaj   +1 more source

Non-viral gene delivery for non-small cell lung cancer. [PDF]

Ann Transl Med
Fung V, Gill NA, Andersen S, Fenton OS.
europepmc   +1 more source

Reflections on immune checkpoint inhibition in non-small cell lung cancer.

, 2014
Konstantinos Leventakos, Aaron S. Mansfield   +1 more
openalex   +1 more source

Domain associated with zinc fingers‐containing NF90‐NF45 complex inhibits m6A modification of primary microRNA by suppressing METTL3/14 activity

FEBS Open Bio, EarlyView.
NF90–NF45 functions as a negative regulator of methyltransferase‐like 3/14 (METTL3/14)‐mediated N6‐methyladenosine (m6A) modification on primary microRNAs (pri‐miRNAs). NF90–NF45 binds to anti‐oncogenic pri‐miRNAs and inhibits their m6A modification, thereby suppressing the biogenesis of anti‐oncogenic miRNAs.
Takuma Higuchi, Shunsuke Morioka, Keiko Morisawa, Kazutsugu Matsukawa, Shingo Ashida, Takeshi Suzuki, Shuji Sakamoto   +6 more
wiley   +1 more source

Cemiplimab in Japanese patients with advanced non-small cell lung cancer. [PDF]

Jpn J Clin Oncol
Sato Y, Tani Y, Ishii H, Katakura S, Oki M, Watanabe Y, Yokoyama T, Naoki K, Pouliot JF, Kaul M, Paccaly A, Visich JE, Kim E, Mani J, Li Y, Lowy I, Seebach F, Mathias M, Ikeda S.   +18 more
europepmc   +1 more source